sulfadiazine has been researched along with Toxoplasmosis, Animal in 65 studies
Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.
diazine : The parent structure of the diazines.
Toxoplasmosis, Animal: Acquired infection of non-human animals by organisms of the genus TOXOPLASMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Infected mice were dosed with MQ solution or MQ-niosomes at 50 mg/kg/day, starting from the second day post-infection (PI) (acute model) or the fifth week PI (chronic model), and this was continued for six consecutive days." | 5.91 | Mefloquine loaded niosomes as a promising approach for the treatment of acute and chronic toxoplasmosis. ( Aboul Asaad, IA; Amer, BS; Carter, WG; El Maghraby, GM; El Sharazly, BM; Ismail, HIH; Mohamed, DA; Yassen, NA, 2023) |
| "In patients with AIDS, toxoplasmosis is the most common cause of CNS mass lesions." | 2.38 | Toxoplasmosis in AIDS patients. ( Tuazon, CU, 1989) |
| " Infected mice were dosed with MQ solution or MQ-niosomes at 50 mg/kg/day, starting from the second day post-infection (PI) (acute model) or the fifth week PI (chronic model), and this was continued for six consecutive days." | 1.91 | Mefloquine loaded niosomes as a promising approach for the treatment of acute and chronic toxoplasmosis. ( Aboul Asaad, IA; Amer, BS; Carter, WG; El Maghraby, GM; El Sharazly, BM; Ismail, HIH; Mohamed, DA; Yassen, NA, 2023) |
| "Fluconazole is an important antifungal triazole used against others CNS related opportunistic pathogens such as Cryptococcus neoformans and Candida spp." | 1.39 | Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model. ( de Souza, W; Martins-Duarte, ÉS; Vommaro, RC, 2013) |
| " annua infusion before infection in HFF cells showed a dose-response inhibitory curve that reached up to 75% of inhibition, similarly to the results observed when parasites were treated with sulfadiazine." | 1.35 | Toxoplasma gondii: effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo. ( Béla, SR; de Oliveira, TC; Ferro, EA; Magalhães, PM; Mineo, JR; Rostkowska, C; Silva, DA, 2009) |
| "Sulfadiazine was withdrawn after 14-21 days to allow reactivation." | 1.34 | The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice. ( Jost, C; Liesenfeld, O; Reiter-Owona, I, 2007) |
| "The compound 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone (PHNQ6) was evaluated for activity against Toxoplasma gondii, alone or combined with sulfadiazine." | 1.33 | Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine. ( Ferreira, RA; Oliveira, AB; Ribeiro, MF; Tafuri, WL; Vitor, RW, 2006) |
| "Mice treated with buprenorphine and not infected with T." | 1.33 | Buprenorphine does not affect acute murine toxoplasmosis and is recommended as an analgesic in Toxoplasma gondii studies in mice. ( Dubey, JP; Goodwin, DG; Kaur, T; Lindsay, DS; Mitchell, SM; Strobl, J, 2005) |
| "Atovaquone was detectable in the sera, brains, livers, and lungs of mice by high-performance liquid chromatography." | 1.31 | Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. ( Borner, K; Hahn, H; Kayser, O; Krause, K; Liesenfeld, O; Müller, RH; Schöler, N, 2001) |
| " The same dose protected 100% of infected mice when administered in combination with non-protective doses of atovaquone, clindamycin or sulphadiazine." | 1.30 | Use of ketolides in combination with other drugs to treat experimental toxoplasmosis. ( Araujo, FG; Bryskier, A; Khan, AA; Remington, JS, 1998) |
| "The activity of recombinant bactericidal/permeability-increasing protein (rBPI21), alone or in combination with sulfadiazine, on the intracellular replication of Toxoplasma gondii was assessed in vitro and in mice with acute toxoplasmosis." | 1.30 | Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii. ( Araujo, FG; Khan, AA; Lambert, LH; Remington, JS, 1999) |
| "The efficacy of roxithromycin alone or in combination with pyrimethamine or sulphadiazine was examined in vitro and in a murine model of acute toxoplasmosis." | 1.29 | In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii. ( Bryskier, A; Derouin, F; Moutot, M; Romand, S, 1995) |
| " The dosage regimen for pyrimethamine and sulfadiazine was established by pharmacokinetic studies in two monkeys." | 1.29 | Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. ( Baars, I; Camps, W; Eskes, T; Galama, J; Melchers, W; Meuwissen, J; Schoondermark-van de Ven, E; Vree, T, 1995) |
| "The efficacy of atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, and minocycline was examined in vitro and in a murine model of acute toxoplasmosis." | 1.29 | In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. ( Derouin, F; Pudney, M; Romand, S, 1993) |
| "The activity of atovaquone in the treatment of murine toxoplasmosis was greatly enhanced when administered in combination with pyrimethamine or sulfadiazine." | 1.29 | The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. ( Araujo, FG; Lin, T; Remington, JS, 1993) |
| "Post-sulfadiazine treatment survival was enhanced in nude mice by reconstitution with either L3T4+ or Lyt-2+ cells and was reduced in euthymic mice by monoclonal antibody treatment directed at depleting either L3T4+ or Lyt-2+ cells or interleukin-2 (IL-2) or interferon-gamma (IFN-gamma)." | 1.29 | Response to treatment for an intracellular infection in a T cell-deficient host: toxoplasmosis in nude mice. ( Hariprashad, J; Murray, HW; Teitelbaum, R, 1993) |
| "Thus epiroprim is an active and potentially less toxic alternative pyrimethamine for the treatment of toxoplasmosis." | 1.29 | Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice. ( Allegra, CJ; Kovacs, JA; Martinez, A, 1996) |
| "Treatment with pyrimethamine plus sulfadiazine produced clinical cures in 100% of the infected mice 1 month after infection." | 1.29 | A clinical-parasitological monotherapy cure in the treatment of experimental infection by a highly virulent strain of Toxoplasma gondii. ( Arribas, JR; de Diego, JA; Penin, P; Vázquez, E; Vázquez, JJ, 1996) |
| "The activity of the macrolide antibiotic clarithromycin was examined alone or in combination with other drugs for the treatment of acute or chronic infections with Toxoplasma gondii in mice." | 1.28 | Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. ( Araujo, FG; Lin, T; Prokocimer, P; Remington, JS, 1992) |
| "When pyrimethamine was administered from day 1, 7 of 11 mice died within 25 days; by determination of parasitic loads, the effect of pyrimethamine was only demonstrable from day 6, and a relapse was constantly observed after the cessation of therapy." | 1.28 | In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. ( Derouin, F; Piketty, C; Pocidalo, JJ; Rouveix, B, 1990) |
| "Five drug regimens for the treatment of acute toxoplasmosis were compared in a monkey model." | 1.27 | Five drug regimens for treatment of acute toxoplasmosis in squirrel monkeys. ( Harper, JS; London, WT; Sever, JL, 1985) |
| "Trimethoprim was found to have no effect." | 1.25 | Chemotherapy in experimental toxoplasmosis: comparison of the efficacy of trimethoprim-sulfur and pyrimethamine-sulfur combinations. ( Seah, SK, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (36.92) | 18.7374 |
| 1990's | 23 (35.38) | 18.2507 |
| 2000's | 7 (10.77) | 29.6817 |
| 2010's | 9 (13.85) | 24.3611 |
| 2020's | 2 (3.08) | 2.80 |
| Authors | Studies |
|---|---|
| El Sharazly, BM | 1 |
| Aboul Asaad, IA | 1 |
| Yassen, NA | 1 |
| El Maghraby, GM | 1 |
| Carter, WG | 1 |
| Mohamed, DA | 1 |
| Amer, BS | 1 |
| Ismail, HIH | 1 |
| Yang, Y | 1 |
| Ren, H | 1 |
| Xin, S | 1 |
| Jiang, N | 1 |
| Si, H | 1 |
| Xu, C | 1 |
| Zhang, J | 2 |
| Zhang, X | 1 |
| Li, B | 1 |
| Zhou, X | 1 |
| Lang, D | 1 |
| Schott, BH | 1 |
| van Ham, M | 1 |
| Morton, L | 1 |
| Kulikovskaja, L | 1 |
| Herrera-Molina, R | 1 |
| Pielot, R | 1 |
| Klawonn, F | 1 |
| Montag, D | 1 |
| Jänsch, L | 1 |
| Gundelfinger, ED | 1 |
| Smalla, KH | 1 |
| Dunay, IR | 1 |
| Tyebji, S | 1 |
| Seizova, S | 1 |
| Garnham, AL | 1 |
| Hannan, AJ | 1 |
| Tonkin, CJ | 1 |
| Silva, LA | 2 |
| Fernandes, MD | 1 |
| Machado, AS | 1 |
| Reis-Cunha, JL | 2 |
| Bartholomeu, DC | 2 |
| Almeida Vitor, RW | 1 |
| Leesombun, A | 1 |
| Boonmasawai, S | 1 |
| Shimoda, N | 1 |
| Nishikawa, Y | 1 |
| Vítor, RW | 3 |
| de Oliveira, TC | 1 |
| Silva, DA | 1 |
| Rostkowska, C | 1 |
| Béla, SR | 1 |
| Ferro, EA | 1 |
| Magalhães, PM | 1 |
| Mineo, JR | 1 |
| Hester, J | 1 |
| Mullins, J | 1 |
| Sa, Q | 1 |
| Payne, L | 1 |
| Mercier, C | 1 |
| Cesbron-Delauw, MF | 1 |
| Suzuki, Y | 1 |
| Ferreira, RA | 2 |
| de Oliveira, AB | 1 |
| Gualberto, SA | 1 |
| Miguel Del Corral, JM | 1 |
| Fujiwara, RT | 1 |
| Gazzinelli Guimarães, PH | 1 |
| de Almeida Vitor, RW | 1 |
| Martins-Duarte, ÉS | 1 |
| de Souza, W | 1 |
| Vommaro, RC | 1 |
| FRANCOIS, J | 1 |
| JADIN, J | 1 |
| WERY, M | 1 |
| VANDECASTEELE, J | 1 |
| Alves, CF | 1 |
| Oliveira, AB | 1 |
| Ribeiro, MF | 1 |
| Tafuri, WL | 1 |
| Lindsay, DS | 1 |
| Kaur, T | 1 |
| Mitchell, SM | 1 |
| Goodwin, DG | 1 |
| Strobl, J | 1 |
| Dubey, JP | 3 |
| Jost, C | 1 |
| Reiter-Owona, I | 1 |
| Liesenfeld, O | 2 |
| Nguyen, BT | 1 |
| Stadtsbaeder, S | 1 |
| Frenkel, JK | 5 |
| Taylor, DW | 1 |
| Bonardi, R | 1 |
| Tabbara, KF | 1 |
| Sakuragi, S | 1 |
| O'Connor, GR | 1 |
| Smith, DD | 1 |
| Gupta, SL | 1 |
| Gautam, OP | 1 |
| Chhabra, MB | 1 |
| Romand, S | 2 |
| Bryskier, A | 2 |
| Moutot, M | 1 |
| Derouin, F | 4 |
| Mehlhorn, H | 1 |
| Dankert, W | 1 |
| Hartman, PG | 1 |
| Then, RL | 1 |
| Schoondermark-van de Ven, E | 1 |
| Galama, J | 1 |
| Vree, T | 1 |
| Camps, W | 1 |
| Baars, I | 1 |
| Eskes, T | 1 |
| Meuwissen, J | 1 |
| Melchers, W | 1 |
| Araujo, FG | 8 |
| Slifer, T | 2 |
| Remington, JS | 8 |
| Pudney, M | 1 |
| Lin, T | 3 |
| Murray, HW | 1 |
| Teitelbaum, R | 1 |
| Hariprashad, J | 1 |
| Martinez, A | 1 |
| Allegra, CJ | 2 |
| Kovacs, JA | 2 |
| Gross, U | 1 |
| Pohl, F | 1 |
| de Diego, JA | 1 |
| Penin, P | 1 |
| Arribas, JR | 1 |
| Vázquez, E | 1 |
| Vázquez, JJ | 1 |
| Miédougé, M | 1 |
| Bessières, MH | 1 |
| Cassaing, S | 1 |
| Swierczynski, B | 1 |
| Séguéla, JP | 1 |
| Schoondermark-van de Ven, EM | 1 |
| Melchers, WJ | 1 |
| Galama, JM | 1 |
| Meuwissen, JH | 1 |
| Eskes, TK | 1 |
| Villard, O | 1 |
| Candolfi, E | 1 |
| Ferguson, DJ | 1 |
| Marcellin, L | 1 |
| Kien, T | 1 |
| Khan, AA | 2 |
| Lambert, LH | 1 |
| Kirisits, MJ | 1 |
| Mui, E | 1 |
| McLeod, R | 1 |
| Schöler, N | 1 |
| Krause, K | 1 |
| Kayser, O | 1 |
| Müller, RH | 1 |
| Borner, K | 1 |
| Hahn, H | 1 |
| Yeary, RA | 1 |
| Lindberg, RE | 1 |
| Sheffield, HG | 1 |
| Melton, ML | 1 |
| Hof, H | 1 |
| Höhne, K | 1 |
| Seeliger, HP | 1 |
| Lai, CH | 1 |
| Tizard, IR | 1 |
| Ingram, DG | 1 |
| Seah, SK | 1 |
| Almadany, R | 1 |
| Chau, F | 1 |
| Rouveix, B | 2 |
| Pocidalo, JJ | 2 |
| Prokocimer, P | 1 |
| Johnson, LL | 1 |
| Chao, CC | 1 |
| Sharp, BM | 1 |
| Pomeroy, C | 1 |
| Filice, GA | 1 |
| Peterson, PK | 1 |
| Escajadillo, A | 1 |
| Piketty, C | 1 |
| Tuazon, CU | 1 |
| Hou, XP | 1 |
| Tao, F | 1 |
| Yi, YY | 1 |
| Wang, WL | 1 |
| Brinkmann, V | 1 |
| Sharma, SD | 1 |
| Chabner, BA | 1 |
| Swan, JC | 1 |
| Drake, J | 1 |
| Lunde, M | 1 |
| Parrillo, JE | 1 |
| Masur, H | 1 |
| Guptill, DR | 1 |
| Harper, JS | 1 |
| London, WT | 1 |
| Sever, JL | 1 |
| Werner, H | 1 |
| Gönnert, R | 1 |
| Markus, MB | 1 |
| Krogstad, DJ | 1 |
| Juranek, DD | 1 |
| Walls, KW | 1 |
| Miller, NL | 1 |
| Brus, R | 1 |
| Chrusciel, TL | 1 |
| Steffen, J | 1 |
| Szaflarski, J | 1 |
3 reviews available for sulfadiazine and Toxoplasmosis, Animal
| Article | Year |
|---|---|
Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cells, Cultured; Clindamycin; Humans; Pyrimet | 1996 |
Effects of morphine addiction on the pathogenesis of murine toxoplasmosis.
Topics: Animals; Disease Susceptibility; Female; Immunologic Deficiency Syndromes; Interferon-gamma; Mice; M | 1991 |
Toxoplasmosis in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Animals; Drug Therapy, Combination; Humans; Mice; Opportunistic | 1989 |
62 other studies available for sulfadiazine and Toxoplasmosis, Animal
| Article | Year |
|---|---|
Mefloquine loaded niosomes as a promising approach for the treatment of acute and chronic toxoplasmosis.
Topics: Animals; Liposomes; Mefloquine; Mice; Pyrimethamine; Sulfadiazine; Toxoplasma; Toxoplasmosis; Toxopl | 2023 |
Comparative Immunological Response and Pathobiology of Mice Inoculated with Toxoplasma gondii Isolated from Different Hosts.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Brain; China; Host-Parasite Interactions; Mice | 2021 |
Licochalcone A: An effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo.
Topics: Animals; Antiprotozoal Agents; Azithromycin; Cell Survival; Chalcones; Inhibitory Concentration 50; | 2018 |
Chronic Toxoplasma infection is associated with distinct alterations in the synaptic protein composition.
Topics: Animals; Antiprotozoal Agents; Brain; Chronic Disease; Cytokines; Disease Models, Animal; Gene Expre | 2018 |
Impaired social behaviour and molecular mediators of associated neural circuits during chronic Toxoplasma gondii infection in female mice.
Topics: Amygdala; Animals; Behavior, Animal; Brain; Cognition; Disease Models, Animal; Female; Hippocampus; | 2019 |
Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil.
Topics: Alcohol Dehydrogenase; Animals; Antiprotozoal Agents; Female; Genotype; Humans; Infant, Newborn; Mic | 2019 |
Effects of Extracts from Thai Piperaceae Plants against Infection with Toxoplasma gondii.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Chlorocebus aethiops; Female; Mice; Mice, Inbred C57 | 2016 |
Genetic Polymorphisms and Phenotypic Profiles of Sulfadiazine-Resistant and Sensitive Toxoplasma gondii Isolates Obtained from Newborns with Congenital Toxoplasmosis in Minas Gerais, Brazil.
Topics: Animals; Antiprotozoal Agents; Base Sequence; Brazil; Dihydropteroate Synthase; Drug Resistance; Fem | 2017 |
Toxoplasma gondii: effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo.
Topics: Animals; Artemisia annua; Biological Assay; Cell Survival; Cells, Cultured; Coccidiostats; Cytokines | 2009 |
Toxoplasma gondii antigens recognized by IgG antibodies differ between mice with and without active proliferation of tachyzoites in the brain during the chronic stage of infection.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antiprotozoal Agents; Brain; Chronic Disease; F | 2012 |
New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains.
Topics: Animals; Antimalarials; Aporphines; Atovaquone; Cells, Cultured; Coccidiostats; Female; Fibroblasts; | 2012 |
Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
Topics: Acute Disease; Animals; Antifungal Agents; Antiprotozoal Agents; Cell Line; Cell Survival; Disease M | 2013 |
[TREATMENT OF TOXOPLASMOSIS. (EXPERIMENTAL STUDY)].
Topics: Anilides; Animals; Anti-Bacterial Agents; Colistin; Mice; Oxytetracycline; Penicillin V; Pyrimethami | 1963 |
Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Coccidiostats; Dose-Response Relationship, Drug; Drug Com | 2005 |
Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine.
Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Female; Mice; Naphthoquinones; Random Allo | 2006 |
Buprenorphine does not affect acute murine toxoplasmosis and is recommended as an analgesic in Toxoplasma gondii studies in mice.
Topics: Acute Disease; Analgesics, Opioid; Animals; Buprenorphine; Cell Line; Chlorocebus aethiops; Coccidio | 2005 |
The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice.
Topics: Animals; Antiprotozoal Agents; Brain; Disease Models, Animal; Drug Administration Schedule; Humans; | 2007 |
Comparative effects of cotrimoxazole (trimethoprim-sulphamethoxazole), pyrimethamine-sulphadiazine and spiramycin during avirulent infection with Toxoplasma gondii (Beverley strain) in mice.
Topics: Animals; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Leucomyci | 1983 |
Toxoplasmosis in immunoglobulin M-suppressed mice.
Topics: Animals; Antibodies; Immunization, Passive; Immunoglobulin M; Immunosuppression Therapy; Mice; Mice, | 1982 |
[Toxoplasmosis].
Topics: Adult; Animals; Antibodies; Antimalarials; Drug Therapy, Combination; Female; Humans; Immunologic Te | 1980 |
Minocycline in the chemotherapy of murine toxoplasmosis.
Topics: Animals; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Male; Mice; Minocycline; P | 1982 |
Immunization of cats against shedding of Toxoplasma oocysts.
Topics: Animals; Antibodies; Cat Diseases; Cats; Feces; Immunization; Mice; Monensin; Parasite Egg Count; Py | 1982 |
Chemotherapeutic efficacy of some agents against experimental toxoplasmosis in mice.
Topics: Animals; Male; Mice; Mice, Inbred Strains; Sulfadiazine; Toxoplasma; Toxoplasmosis, Animal | 1981 |
In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cells, Cultured; Drug Combinations; Female; F | 1995 |
A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Dapsone; Drug Therapy, Combination; Female; F | 1995 |
Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine.
Topics: Administration, Oral; Animals; Female; Half-Life; Macaca mulatta; Maternal-Fetal Exchange; Metabolic | 1995 |
Rifabutin is active in murine models of toxoplasmosis.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Brain; Clindamycin; Drug Therapy, Combination; Female; Mi | 1994 |
In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Clarithromycin; Coccidiostats; Drug Combinations; Drug In | 1993 |
The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Drug Synergism; Drug Therapy, Combination; Female; Mice; | 1993 |
Response to treatment for an intracellular infection in a T cell-deficient host: toxoplasmosis in nude mice.
Topics: Animals; Antibodies, Monoclonal; Cells, Cultured; Female; Macrophages; Mice; Mice, Inbred BALB C; Mi | 1993 |
Nonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondii.
Topics: Animals; Anti-Infective Agents; Cytokines; Drug Synergism; Encephalitis; Female; Lymphocyte Activati | 1995 |
Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.
Topics: Acute Disease; Administration, Oral; Animals; Anti-Infective Agents; Antiprotozoal Agents; Dapsone; | 1996 |
A clinical-parasitological monotherapy cure in the treatment of experimental infection by a highly virulent strain of Toxoplasma gondii.
Topics: Animals; Antiprotozoal Agents; Brain; Drug Evaluation, Preclinical; Drug Therapy, Combination; Mice; | 1996 |
Parasitemia and parasitic loads in acute infection and after anti-gamma-interferon treatment in a toxoplasmic mouse model.
Topics: Acute Disease; Animals; Anti-Infective Agents; Antibodies; Brain; Chronic Disease; Drug Therapy, Com | 1997 |
Prenatal diagnosis and treatment of congenital Toxoplasma gondii infections: an experimental study in rhesus monkeys.
Topics: Amniotic Fluid; Animals; Anti-Infective Agents; Disease Models, Animal; DNA, Protozoan; DNA, Ribosom | 1997 |
Loss of oral infectivity of tissue cysts of Toxoplasma gondii RH strain to outbred Swiss Webster mice.
Topics: Animals; Antigens, Protozoan; Antiprotozoal Agents; Brain; Female; Fluorescent Antibody Technique; M | 1997 |
Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
Topics: Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Atovaquone; Clindamycin; Drug Therapy, Combina | 1998 |
Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.
Topics: Animals; Antimicrobial Cationic Peptides; Antiprotozoal Agents; Blood Proteins; Cells, Cultured; Dis | 1999 |
Measurement of the efficacy of vaccines and antimicrobial therapy against infection with Toxoplasma gondii.
Topics: Animals; Antiprotozoal Agents; Electrophoresis, Polyacrylamide Gel; Female; Mice; Mice, Inbred BALB | 2000 |
Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Brain; Chromatography, High Pressure Liquid; Injections, | 2001 |
Anticoccidial activity of 2-sulfamoyl-4,4-diaminodiphenylsulfone, sulfadiazine, pyrimethamine and clindamycin in cats infected with Toxoplasma gondii.
Topics: Animals; Cat Diseases; Cats; Clindamycin; Coccidiostats; Pyrimethamine; Sulfadiazine; Sulfonamides; | 1977 |
Toxoplasmosis in nude mice.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Immunization, Passive; Mice; Mice, Nude; Sulfadiazine; Thym | 1977 |
Effects of pyrimethamine and sulfadiazine on the intestinal development of Toxoplasma gondii in cats.
Topics: Animals; Antibody Formation; Cat Diseases; Cats; Immunization; Intestines; Parasite Egg Count; Pyrim | 1976 |
Macrophage function and host resistance against infection with Toxoplasma gondii.
Topics: Animals; Carbon; Dextrans; Female; Immunity; Macrophages; Mice; Pertussis Vaccine; Spleen; Splenecto | 1976 |
The protective effect of milk diet on Toxoplasma gondii infection in mice.
Topics: Aminobenzoates; Animals; Antibodies; Diet; Drug Resistance; Injections, Intraperitoneal; Injections, | 1975 |
Chemotherapy in experimental toxoplasmosis: comparison of the efficacy of trimethoprim-sulfur and pyrimethamine-sulfur combinations.
Topics: Animals; Drug Combinations; Drug Evaluation; Female; Mice; Pyrimethamine; Sulfadiazine; Sulfamethoxa | 1975 |
Synergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in mice.
Topics: Animals; Azithromycin; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Erythromyc | 1992 |
Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis.
Topics: Animals; Azithromycin; Brain; Drug Synergism; Drug Therapy, Combination; Erythromycin; Female; Lung; | 1992 |
Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Animals; Brain Diseases; Chronic Disease; Clarith | 1992 |
SCID mouse models of acute and relapsing chronic Toxoplasma gondii infections.
Topics: Acute Disease; Animals; Brain Diseases; Chronic Disease; Cysts; Disease Models, Animal; Lymphocytes; | 1992 |
Experimental toxoplasmosis and vaccine tests in Aotus monkeys.
Topics: Animals; Antibodies, Protozoan; Aotus trivirgatus; Disease Models, Animal; Female; Hypersensitivity, | 1991 |
In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice.
Topics: Animals; Anti-Infective Agents; Brain; Clindamycin; Female; Kinetics; Lung; Mice; Pyrimethamine; Sul | 1990 |
[Surface charged liposomes as drug carriers and in vivo tests of mice infected with toxoplasma].
Topics: Animals; Drug Carriers; Electrochemistry; Liposomes; Mice; Pyrimethamine; Sulfadiazine; Toxoplasmosi | 1989 |
Different regulation of the L3T4-T cell subset by B cells in different mouse strains bearing the H-2k haplotype.
Topics: Animals; Antigen-Presenting Cells; Antigens, Differentiation, T-Lymphocyte; Antigens, Surface; B-Lym | 1986 |
Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii.
Topics: Animals; Cells, Cultured; Drug Therapy, Combination; Folic Acid Antagonists; Macrophages; Mice; Mice | 1987 |
In vivo activity of piritrexim [corrected] against Toxoplasma gondii.
Topics: Animals; Anti-Infective Agents; Drug Combinations; Drug Evaluation, Preclinical; Mice; Pyrimethamine | 1987 |
Five drug regimens for treatment of acute toxoplasmosis in squirrel monkeys.
Topics: Animals; Clindamycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leuco | 1985 |
[The effect of nifurtimox on intra- and extracellular development stages of Toxoplasma gonii].
Topics: Animals; Antitrichomonal Agents; Cyclic S-Oxides; Drug Combinations; Drug Evaluation, Preclinical; F | 1974 |
Symptoms, transmission, prevention and treatment of toxoplasmosis.
Topics: Adult; Animals; Cat Diseases; Cats; Child; Dogs; Female; Humans; Infant; Infant, Newborn; Lymph Node | 1973 |
Toxoplasmosis. With comments on risk of infection from cats.
Topics: Animals; Cat Diseases; Cats; Feces; Female; Food Contamination; Humans; Male; Meat; Pregnancy; Pregn | 1972 |
Toxoplasma gondii life cycle in cats.
Topics: Animals; Antigens; Carrier State; Cat Diseases; Cats; Feces; Intestines; Isospora; Mice; Pyrimethami | 1970 |
Antitoxoplasmic activity of sulfonamides with various radicals in experimental toxoplasmosis in mice.
Topics: Animals; Meprobamate; Mice; Pyrimidines; Sulfadiazine; Sulfadimethoxine; Sulfisomidine; Sulfonamides | 1971 |